SAB Biotherapeutics (SABS) Retained Earnings: 2020-2025
Historic Retained Earnings for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$94.0 million.
- SAB Biotherapeutics' Retained Earnings rose 16.64% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.0 million, marking a year-over-year increase of 16.64%. This contributed to the annual value of -$124.2 million for FY2024, which is 37.87% down from last year.
- SAB Biotherapeutics' Retained Earnings amounted to -$94.0 million in Q3 2025, which was up 32.59% from -$139.5 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Retained Earnings registered a high of $3.0 million during Q1 2021, and its lowest value of -$139.5 million during Q2 2025.
- In the last 3 years, SAB Biotherapeutics' Retained Earnings had a median value of -$95.1 million in 2024 and averaged -$97.5 million.
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 4,419.73% in 2022, then climbed by 16.64% in 2025.
- Quarterly analysis of 5 years shows SAB Biotherapeutics' Retained Earnings stood at -$29.1 million in 2021, then tumbled by 64.34% to -$47.9 million in 2022, then crashed by 88.14% to -$90.1 million in 2023, then slumped by 37.87% to -$124.2 million in 2024, then climbed by 16.64% to -$94.0 million in 2025.
- Its last three reported values are -$94.0 million in Q3 2025, -$139.5 million for Q2 2025, and -$129.4 million during Q1 2025.